Attention Deficit Hyperactivity Disorder Market – By Drug Type, By Age Group, By Gender, By Dosage Form, By Distribution Channel & Global Forecast, 2024 to 2032

Attention Deficit Hyperactivity Disorder Market Size

The global attention deficit hyperactivity disorder market size was valued at USD 15.8 billion in 2023 and is estimated to grow at a CAGR of over 5.1% from 2024 to 2032. Several factors such as the worldwide increase in ADHD cases, improvements in technology, and innovative treatments are fuelling the growth of the ADHD market. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., roughly 7 million children aged 3-17 years old, which is about 11.4%, were affected by ADHD in 2022.
 

Moreover, the increase in disorder awareness and comprehension drives the market demand for better diagnosis and treatment solutions. Also, the range of available treatment methods for ADHD is growing with the advent of both drug and non-drug therapies. Medications such as stimulants (e.g., methylphenidate, amphetamines) remain the standard treatment, but non-stimulant drugs and behavioral therapies are gaining popularity. And finally, new formulations of drugs with fewer side effects are being developed for patients of all ages.
 

Attention Deficit Hyperactivity Disorder (ADHD) is a common mental illness among both children and adults where the affected tend to be easily distractible, exhibit hyperactive behavior, and show impulsivity. Market refers to the space in which the diagnosis, treatment, and management of attention deficit hyperactivity disorder are performed. It covers the range of medicines, education and training, and tools and services for diagnosis and other support services to enhance the outcomes of children and adults.
 

Attention Deficit Hyperactivity Disorder Market Trends

• Diagnosis of attention deficit hyperactivity disorder being on the rise is one of the major factors that supports the growth of the ADHD marketplace. Parents and other caregivers, as well as some health practitioners, with an enhanced understanding of the condition, along with the availability of efficient diagnostic processes, have contributed to the increase in ADHD diagnosis.
   
• Furthermore, public health campaigns and educational initiatives have contributed positively toward the reduction of stigma associated with ADHD, prompting many people to seek diagnosis and treatment.
   
• Further growth is even more supported by new developments in the digital health industry improving access to doctors and new medication making it easier to treat ADHD. As a result, since more people are getting diagnosed, they have become a bigger target market which enhances ADHD medication and therapy usage.
   

Attention Deficit Hyperactivity Disorder Market Analysis

Based on drug type, the market is segmented into stimulants and non-stimulants. The stimulant segment is further bifurcated into amphetamine, methylphenidate, lisdexamfetamine, dexmethylphenidate, and dextroamphetamine. The stimulants segment dominated the market with USD 11.2 billion in 2023.
 

• Stimulants are the most common medications for attention deficit hyperactivity disorder. They increase the amounts of dopamine and norepinephrine in the brain which increases the ability to pay attention, focus, and control impulses. The two most common stimulants are methylphenidate and amphetamines.
   
• Over two-thirds of all patients (70-80%) that are administered these stimulants perform positive outcomes tests. Due to their effectiveness and speed, stimulants have become the first-line treatment for attention deficit hyperactivity disorder. They aid in decreasing hyperactive behavior while also increasing the level of social interactions and work completed.
   
• Many practitioners avoid using stimulants due to their suboptimal safety profile, dependency issues, and possible cardiovascular complications. Dependent patients may need prescription non-stimulants, but these are generally proven to be ineffective. Individualized plans must be prepared based on long-term studies conducted for optimal sustained outcomes.

Based on age group, the attention deficit hyperactivity disorder market is divided into children and adults. The children segment accounted for a significant market share of 67.1% in 2023.
 

• Symptoms for children that exhibit impulsive behavior alongside hyperactivity and inattention could lead to negative consequences to their academics as well as social life, which can be summarized as ADHD.
   
• With the aforementioned difficulties, some children may exhibit problems with interpersonal relationships, achieve less in school as well as exhibit behavioral issues. Children diagnosed with attention deficit hyperactivity disorder will be affected in their ability to concentrate on class activities, complete chores, listen and pay attention to instructions, as well as self-regulate in different contexts.
   
• Attention deficit hyperactivity disorder symptoms can be effectively managed using a combination of behavior modification techniques, education, and in some cases medication, which makes early intervention fundamentally important. Patients suffering from ADHD show better outcomes when the condition within the children is diagnosed properly and early enough.
   

Based on gender, the attention deficit hyperactivity disorder market is divided into male and female. The male segment dominated the market with USD 10.4 billion in 2023.
 

• Attention Deficiency and Hyperactivity Disorder remains one of the most neglected subjects among parents with a strong bias on affecting more boys than girls. For example, the Centers for Disease Control and Prevention (CDC) indicates that boys are diagnosed with the disorders almost three times higher than girls, with about 13% of boys aged 3-17. As a result, these behaviors are often more pronounced in males than females leading to faster identification and intervention for gender differences.
   
• Boys with ADHD often struggle in school, personal relationships, and behavior treatment. Boys are hyperactive and impulsive, making it difficult for them to adhere to instructions and for their teachers to control their behavior. Such children tend to get into trouble in school.
   

Based on dosage form, the attention deficit hyperactivity disorder market is divided into tablets, capsules, and other dosage forms. The tablets segment dominated the market with USD 9.2 billion in 2023 and is expected to reach 14.2 billion within the forecast period.
 

• Such dosage forms for ADHD are very common in the shape of pills, especially the ones that act as stimulants such as Methylphenidate (Ritalin) or Amphetamines (Adderall). These pills have dosage forms that are either immediately dissolving (IR) or dissolving over an extended period (XR), thus providing flexibility to the child or adult that consumes them.
   
• Additionally, to manage ADHD symptoms with several doses, immediate tablets are usually prescribed. On the other hand, patients who experience these symptoms can be much better treated with extended-release formulations, as they will only need to take one tablet a day. Such people benefit greatly from the extended-release tablets, as they do not need to worry about taking additional pills in the middle of the day.
   

Based on distribution channel, the attention deficit hyperactivity disorder market is divided into retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy segment dominated the market with USD 9.3 billion in 2023.
 

• The distribution of ADHD medications has and will always have a reliance on retail pharmacies, accessibility is ensured to the greater population. Prescriptions filling and prescription management consultation services are highly sought from these pharmacies by ADHD patients or their caregivers along with management of medication side effects.
   
• Furthermore, retail pharmacies have the added advantage of providing convenience as many patients, due to monthly regulations over certain controlled substances prescriptions, visit these pharmacies on a monthly basis. Insurance checking and medication interaction with other drugs are also done by pharmacists.
   
• Additionally, as ADHD treatments gain popularity, retail pharmacies are now putting greater focus on patient education and compliance to prescribed doses and refills.

The U.S. attention deficit hyperactivity disorder market is expected to grow at a 5.1% CAGR, to reach USD 10.2 billion by the end of 2032.
 

• The ADHD market in the U.S. is quite mature due to the relative awareness and high diagnosis rates. The U.S. market is equally large since there is a balance between medication and behavioral therapy industries, Adderall and Ritalin are at the top of the prescriptions list.
   
• Medications as well as Cognitive Therapy for ADHD are fundamental to be covered by insurance. In addition, therapeutics of some sort has been developed that is expected to introduce further innovation into the U.S. market for ADHD. This greatly expands market potential making the U.S. ADHD market more competitive.
   

Germany attention deficit hyperactivity disorder market is experiencing robust growth in the Europe market.
 

• Medical scopes and behavioral perspectives assist and have an impact on the growth of this market. Children having ADHD in Germany accounts for about 4.4%, as per NIH.
   
• With the change in consumption, the Germans together with other western powers have moved to focusing on pharmaceuticals only when necessary. Changes in prescriptions for ADHD have shown that Behavioral type interventions are far more effective, especially with smaller children.
   
• Furthermore, due to global trends more and more teenagers and adults have started using stimulants, particularly Methylphenidate, which is considered too mainstream and overused in the Western world.
   

Asia Pacific attention deficit hyperactivity disorder market is witnessing substantial growth of 5.4% during the analysis period.
 

• According to the National Institutes of Health (NIH), in China, approximately 6% of children aged 6 to 12 have ADHD, depicting an untapped potential in the pharmaceutical market. Even though the diagnosis rates of Attention Deficit Hyperactivity Disorder are on the rise, cultural beliefs in traditional medicine and the preference to meditate educational interventions over medicinal solutions are acting as barriers for China to unlock its true potential.
   
• Moreover, as mental health becomes a popular conversation topic, urban areas are expected to tend to their ADHD resources, which will, in turn, positively impact the Chinese market. Currently, the government is actively supporting initiatives that are targeted toward spreading awareness and increasing the availability of solutions for customers suffering from ADHD.
   

Brazil attention deficit hyperactivity disorder market is experiencing robust growth in the Latin America market.
 

• According to Brazil's Ministry of Health, an estimated 5%-6% of school-aged children in Brazil are affected by ADHD. With a nearly zero barrier to entry, people seeking help from specialists are experiencing astronomical rates of ADHD diagnosis over the last decade. Unfortunately, as treatment is dependent on prescription medication, accessibility is highly dependent on region.
   
• Proper attention is being geared towards non-pharmaceutical solutions in ADHD in Brazil, particularly in urban areas. The initiatives taken by the government to enhance knowledge pertaining to ADHD alongside healthcare facilities have propelled market growth, and this growth is anticipated to persist further as attention towards ADHD rises in healthcare policies adoption.
   

Saudi Arabia attention deficit hyperactivity disorder market is witnessing substantial growth during the analysis period.
 

• In the past few years, knowledge of ADHD in Saudi Arabia has expanded significantly. In comparison to western countries, children diagnosed with ADHD in Saudi are still on the lower side. The Ministry of Health Saudi estimated about 3-5 percent of children might be suffering from ADHD. The cultural views towards mental health and lack of specialized practitioners made diagnosing and treating patients rather difficult. These days, however, the government is looking forward to changing the mental health scenario, which will further expand the resources available.
   
• With regards to medicines, the Saudi ADHD market is more inclined towards Methylphenidate while the interest in cognitive as well as behavioral therapy is on the rise. Since Mental health is becoming a potent issue in Saudi healthcare plans, the ADHD market is forecasted to escalate due to increased diagnosis and availability of treatment alternatives.
   

Attention Deficit Hyperactivity Disorder Market Share

In the ADHD medication market, competition is intense due to the rise in people being diagnosed and the need for treatment. Competitors include large pharmaceutical firms that have a variety of therapeutic products and significant market share. Lead players strive to broad base their services for pediatric and adults with ADHD.
 

They utilize mergers and acquisitions to strengthen their market position. These robust players invest in further research and development to target new market segments and meet the growing demands of both stimulant and non-stimulant therapies and thus expand their global presence in the ADHD treatment market.
 

Attention Deficit Hyperactivity Disorder Market Companies

Major players operating in the attention deficit hyperactivity disorder industry are:

• Aytu BioPharma
• Eli Lilly and Company
• Ironshore
• Janssen Pharmaceuticals
• Lupin
• Mallinckrodt
• Novartis
• Pfizer
• Sun Pharmaceutical
• Supernus Pharmaceutical
• Takeda Pharmaceutical Company
• Teva Pharmaceutical
   

USPs of the top market players

• Eli Lilly has created Strattera, an ADHD drug that is non stimulant and provides an option for patients that needs to avoid stimulant therapy. This diversification strategy reinforces their status as one of the leaders in patient focused ADHD care.
   
• Novartis has continued to invest in the advanced research and marketing of Ritalin and its extended release versions due to its worldwide brand recognition and effectiveness in controlling ADHD. This helps ensure their competitive edge over other players in the ADHD market.
   
• Vyvanse, a product of Takeda Pharmaceuticals, is one of the most commonly prescribed drugs for ADHD. It is also the first prodrug which permits the company to market itself as a leader in long acting ADHD therapeutics.
   
• Adhering to the principle of safety over everything, Supernus Pharmaceuticals has focused on developing Qelbree, an extended release non stimulant therapy for ADHD which reduces the risk of stimulant abuse among children.
   

Attention Deficit Hyperactivity Disorder Industry News

• In October 2024, Aytu BioPharma entered into an exclusive collaboration with Lupin Pharma Canada Ltd. to market Adzenys XR-ODT and Cotempla XR-ODT in Canada. This agreement was expected to strengthen the company's foothold in the Canadian ADHD market.
   
• In August 2023, Mallinckrodt received U.S. FDA approval for Lisdexamfetamine Dimesylate Capsules. The medication was indicated in the treatment of ADHD. This approval marked an important milestone in the expansion of Mallinckrodt's product portfolio.
   

The attention deficit hyperactivity disorder market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Stimulants    
  • Amphetamine
  • Methylphenidate
  • Lisdexamfetamine
  • Dexmethylphenidate
  • Dextroamphetamine 
• Non-stimulants        
  • Atomoxetine
  • Guanfacine
  • Clonidine
  • Other non-stimulants

Market, By Age Group

• Children
• Adults

Market, By Gender

• Male
• Female

Market, By Dosage Form

• Tablets
• Capsules
• Other dosage forms

Market, By Distribution Channel

• Retail pharmacy
• Hospital pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• MEA
  • South Africa
  • Saudi Arabia
  • UAE